On April 1st, Reshma Kewalramani assumed the positon of CEO at NEC member Vertex. Dr. Kewalramani was announced as the new CEO—and the company’s first female CEO–last July.
Dr. Kewalramani suceeds Dr. Jeffrey Leiden, who led Vertex for seven years and helped it to become one of Massachusetts’ most competitive and successful biotech companies. He was honored by the Council as a New Englander of the Year in 2018. Dr. Kewalramani joined Vertex in 2018 and has shown expertise in knowing which drug candidates are worth investing in and which to stop researching. Vertex is expected to work on drug candidates for alpha-1 antitrypsin deficiency, which can cause disease in the liver and lungs. Dr. Kewalramani discussed five possible treatments at a J.P.Morgan conference in January.
“These are very big ideas that are really transformative for each field. They’re stretching the boundaries of science. It’s really exciting,” she said. “It’s risky, but I think it’s a risk they can take.”
The New England Council congratulates Dr. Kewalramani and wishes her much success in her new role. Boston Business Journal reports.
Recently from the Blog
November 24 Weekly Round-Up: NEC Members Contribute to COVID-19 Crisis Response